Research programme: coronavirus neutralising antibodies - Brii Biosciences/The Third People's Hospital of Shenzhen/Tsinghua University
Alternative Names: SARS-CoV-2-neutralizing antibodies - Tsinghua University/3rd Peoples Hospital of Shenzhen/Brii BiosciencesLatest Information Update: 28 May 2024
At a glance
- Originator The Third People's Hospital of Shenzhen; Tsinghua University
- Developer Brii Biosciences; The Third People's Hospital of Shenzhen; Tsinghua University
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 May 2024 No recent reports of development identified for research development in COVID-2019-infections(Prevention) in China (Parenteral)
- 28 Apr 2024 No recent reports of development identified for research development in COVID-2019-infections in China (Parenteral)
- 03 Apr 2020 Early research in COVID-2019 infections (Prevention) in China (Parenteral)